Triple threat against melanoma: drug + supercharged immune cells show promise
NCT ID NCT01659151
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a powerful combination for people with advanced melanoma that has spread. The approach uses a targeted drug (vemurafenib), immune cells grown from the patient's own tumor (TIL), and high-dose IL-2 to boost the immune system. The study enrolled 17 participants and measured how many were alive and tumor-free at 12 months. Because it was small and had no comparison group, the results are preliminary but may guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vemurafenib (Zelboraf), tumor-infiltrating lymphocytes (TIL), and high-dose interleukin-2 (IL-2, aldesleukin)
- What this could lead to
- If this combination works, it could point toward a more effective treatment for advanced melanoma that uses the body's own immune cells.
- What could go wrong
- This was a very small, early-phase trial (17 people) with no control group, so results may not apply broadly. The treatment involves strong chemotherapy and high-dose IL-2, which can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma